Starting and financing a biotech company is not a piece of cake. But closing partnerships and progressively bigger financing rounds, bringing molecules into clinical development and eventually floating a company on the stock market is even harder. Molecular partners has done all of that. The biotech, which emanated out of research of the University of Zürich, is developing DARPins® therapeutics, a new class of small protein therapeutic agents, with high-specificity, potency and versatility in one therapy. The lead compound is partnered with Allergan and currently in phase III. And in 2014, the company successfully floated on the Swiss Stock Exchange.